Medication Adjustments When Adding Insulin, GLP-1 RA, or SGLT2i
When Adding GLP-1 RA or SGLT2i
When initiating GLP-1 RA or SGLT2i in patients with type 2 diabetes, sulfonylureas and basal insulin doses should be reduced by 20-50% to prevent hypoglycemia, while metformin should be continued at full dose. 1
Specific Medication Adjustments:
| Medication Class | When Adding GLP-1 RA | When Adding SGLT2i | When Adding Insulin |
|---|---|---|---|
| Metformin | Continue unchanged | Continue unchanged | Continue unchanged |
| Sulfonylureas | Reduce dose by 50% or discontinue | Reduce dose by 50% or discontinue | Reduce dose by 50% or discontinue |
| DPP-4 inhibitors | DISCONTINUE (redundant mechanism) | Continue unchanged | Continue unchanged |
| Pioglitazone | Continue unchanged | Continue unchanged | Use with extreme caution or discontinue (fluid retention risk with insulin) |
| Basal Insulin | Reduce by 20% initially | Reduce by 20% initially | N/A |
| Bolus Insulin | Reduce by 10-20% per meal | Reduce by 10-20% per meal | N/A |
| SGLT2i | Continue unchanged | N/A | Continue unchanged |
| GLP-1 RA | N/A | Continue unchanged | Continue unchanged |
When Adding Basal Insulin
When initiating basal insulin, sulfonylureas should be reduced by 50% or discontinued entirely, while metformin, GLP-1 RA, and SGLT2i should be continued at their current doses. 1
Key Principles:
Metformin continuation is universal: Metformin should be maintained throughout all treatment intensifications unless contraindicated by renal function (eGFR < 30 mL/min/1.73m²) 1
GLP-1 RA and SGLT2i are complementary to insulin: These agents work through insulin-independent mechanisms and should be continued when adding insulin. In fact, if not already prescribed, they should be added to insulin therapy in patients with cardiovascular disease, heart failure, or chronic kidney disease, independent of HbA1c levels 2, 1
Hypoglycemia-causing agents require dose reduction: Sulfonylureas pose the highest hypoglycemia risk when combined with insulin and should be reduced by 50% or discontinued. If basal insulin is already present when adding GLP-1 RA or SGLT2i, reduce basal insulin by approximately 20% 1
Critical Caveats:
DPP-4 inhibitors must be discontinued when starting GLP-1 RA due to overlapping incretin mechanisms—continuing both provides no additional benefit and increases cost 1
Pioglitazone with insulin carries significant fluid retention and heart failure risk—avoid this combination in patients with any history of heart failure or volume overload 1
SGLT2i with insulin increases DKA risk in type 1 diabetes but remains safe in type 2 diabetes when patients are counseled on sick-day management 3, 4
In elderly patients (≥75 years), exercise particular caution when combining multiple glucose-lowering agents, as polypharmacy complexity increases adverse event risk 5
Combination Therapy Rationale:
The combination of GLP-1 RA plus SGLT2i is particularly synergistic, as they reduce cardiovascular events through different mechanisms (anti-atherogenic/anti-inflammatory for GLP-1 RA versus hemodynamic for SGLT2i) 6, 7. This combination should be strongly considered in patients with established cardiovascular disease or multiple cardiovascular risk factors, independent of current glycemic control 2.
When basal insulin is already optimized (fasting glucose at goal but HbA1c remains elevated), adding GLP-1 RA is preferred over adding prandial insulin, as it addresses postprandial hyperglycemia without the weight gain and hypoglycemia risk of bolus insulin 1. Fixed-ratio combination products (insulin/GLP-1 RA) can simplify this regimen.